Avid Bioservices Inc (CDMO)

[freethemice]

They just published phase I results
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
European Journal of Cancer, Vol 49, issue 1, Jan 2013, pp 35-44.
http://www.sciencedirect.com/science/article/pii/S095980491200576X
Conclusions
The MTD of Selectikine with or without cyclophosphamide administered under this schedule was 0.6 mg/kg.
The recommended phase II dose was 0.45–0.6 mg/kg. Selectikine had a favourable safety profile and induced biological effects typical for IL-2.

There have been two phase I trials completed. The first one is the subject of the above paper.
EMD 521873 in Advanced Solid Tumors, MTD Finding
http://www.clinicaltrials.gov/ct2/show/NCT01032681?term=EMD+521873&rank=1
EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)
http://www.clinicaltrials.gov/ct2/show/NCT00879866?term=EMD+521873&rank=2